Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $18.26M fell 15.6% year over year, behind the -9.4% change in trailing-twelve-month research & development. Sequentially, it fell 20.4% from the prior quarter. Over 3 fiscal years it compounded at -6.8% a year.
Context
- Research & development amounted to 276.5% of revenue in FY2025, down 141.7 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -15.6% toward the trailing-twelve-month pace of -9.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 85.47M USD
- Year-over-year change
- -9.6%
- 4-year CAGR
- +1.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.47M | -9.6% |
| FY2024 | 2024-12-31 | 94.53M | -13.8% |
| FY2023 | 2023-12-31 | 109.69M | +3.9% |
| FY2022 | 2022-12-31 | 105.62M | +31.5% |
| FY2021 | 2021-12-31 | 80.33M | — |
Research & Development vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 research & development of $82.1M is the 6th highest of the 11 companies compared; the peer median is $83.78M.
- Its year-over-year change of -9.4% is the 7th highest of 11, against a peer median of +10.7%.
- Research & development amounts to 290.9% of revenue for FHTX, versus a peer median of 216.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $76.25M | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $30.71M | -36.7% | +16.2% | — |
| Peer median (excluding FHTX) | $83.78M | +10.7% | +4.1% | 216.6% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.